全文获取类型
收费全文 | 2913篇 |
免费 | 204篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 45篇 |
妇产科学 | 28篇 |
基础医学 | 579篇 |
口腔科学 | 21篇 |
临床医学 | 270篇 |
内科学 | 578篇 |
皮肤病学 | 45篇 |
神经病学 | 482篇 |
特种医学 | 68篇 |
外科学 | 397篇 |
综合类 | 16篇 |
预防医学 | 149篇 |
眼科学 | 34篇 |
药学 | 183篇 |
中国医学 | 1篇 |
肿瘤学 | 220篇 |
出版年
2023年 | 26篇 |
2022年 | 32篇 |
2021年 | 76篇 |
2020年 | 39篇 |
2019年 | 57篇 |
2018年 | 67篇 |
2017年 | 37篇 |
2016年 | 55篇 |
2015年 | 84篇 |
2014年 | 95篇 |
2013年 | 158篇 |
2012年 | 204篇 |
2011年 | 235篇 |
2010年 | 131篇 |
2009年 | 126篇 |
2008年 | 173篇 |
2007年 | 180篇 |
2006年 | 180篇 |
2005年 | 169篇 |
2004年 | 153篇 |
2003年 | 128篇 |
2002年 | 134篇 |
2001年 | 60篇 |
2000年 | 59篇 |
1999年 | 70篇 |
1998年 | 33篇 |
1997年 | 27篇 |
1996年 | 17篇 |
1995年 | 13篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 28篇 |
1991年 | 32篇 |
1990年 | 29篇 |
1989年 | 19篇 |
1988年 | 16篇 |
1987年 | 22篇 |
1986年 | 14篇 |
1985年 | 17篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1975年 | 6篇 |
1974年 | 7篇 |
1973年 | 7篇 |
1972年 | 6篇 |
1971年 | 5篇 |
排序方式: 共有3123条查询结果,搜索用时 15 毫秒
71.
72.
Christelle Dufour Stephanie Foulon Anne Geoffray Julien Masliah-Planchon Dominique Figarella-Branger Valerie Bernier-Chastagner Laetitia Padovani La Guerrini-Rousseau Cecile Faure-Conter Celine Icher Anne-Isabelle Bertozzi Pierre Leblond Tasnime Akbaraly Franck Bourdeaut Nicolas Andr Celine Chapp Pascale Schneider Emilie De Carli Pascal Chastagner Claire Berger Julien Lejeune Christine Soler Natacha Entz-Werl Marie-Bernadette Delisle 《Neuro-oncology》2021,23(7):1163
BackgroundHigh-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5–19 years with newly diagnosed high-risk medulloblastoma treated according to the phase II trial PNET HR+5.MethodsAll children received postoperative induction chemotherapy (etoposide and carboplatin), followed by 2 high-dose thiotepa courses (600 mg/m2) with hematological stem cell support. At the latest 45 days after the last stem cell rescue, patients received risk-adapted craniospinal radiation therapy. Maintenance treatment with temozolomide was planned to start between 1–3 months after the end of radiotherapy. The primary endpoint was PFS. Outcome and safety analyses were per protocol (all patients who received at least one dose of induction chemotherapy).ResultsFifty-one patients (median age, 8 y; range, 5–19) were enrolled. The median follow-up was 7.1 years (range: 3.4–9.0). The 3 and 5-year PFS with their 95% confidence intervals (95% CI) were 78% (65–88) and 76% (63–86), and the 3 and 5-year OS were 84% (72–92) and 76% (63–86), respectively. Medulloblastoma subtype was a statistically significant prognostic factor (P-value = 0.039) with large-cell/anaplastic being of worse prognosis, as well as a molecular subgroup (P-value = 0.012) with sonic hedgehog (SHH) and group 3 being of worse prognosis than wingless (WNT) and group 4. Therapy was well tolerated.ConclusionsThis treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma. 相似文献
73.
Alexey A. Shadrin PhD Sören Mucha PhD David Ellinghaus PhD Mary B. Makarious BSc Cornelis Blauwendraat PhD Ashwin A.K. Sreelatha MSc Antonio Heras-Garvin PhD Jinhui Ding PhD Monia Hammer PhD Alexandra Foubert-Samier MD Wassilios G. Meissner MD Olivier Rascol PhD Anne Pavy-Le Traon MD Oleksandr Frei PhD Kevin S. O'Connell PhD Shahram Bahrami PhD Stefan Schreiber MD Wolfgang Lieb MD Martina Müller-Nurasyid PhD Ulf Schminke MD Georg Homuth PhD Carsten O. Schmidt PhD Markus M. Nöthen MD Per Hoffmann PhD Christian Gieger PhD Gregor Wenning MD for the European Multiple System Atrophy Study Group J. Raphael Gibbs PhD Andre Franke PhD John Hardy PhD Nadia Stefanova PhD Thomas Gasser MD Andrew Singleton PhD Henry Houlden MD Sonja W. Scholz MD Ole A. Andreassen PhD Manu Sharma PhD 《Movement disorders》2021,36(2):449-459
74.
75.
C. Therrien B. Serhir M. Blanger-Collard J. Skrzypczak D. K. Shank C. Renaud J. Girouard V. Loungnarath M. Carrier G. Brochu F. Tourangeau B. Gilfix A. Piche R. Bazin R. Gurin M. Lavoie V. Martel-Laferrire C. Fortin A. Benoit D. Marcoux N. Gauthier A. M. Laumaea R. Gasser A. Finzi M. Roger 《Journal of clinical microbiology》2021,59(3)
76.
Benjamin Fournier Maud Tusseau Marine Villard Christophe Malcus Emilie Chopin Emmanuel Martin Debora Jorge Cordeiro Nicole Fabien Mathieu Fusaro Alexandra Gauthier Nathalie Garnier David Goncalves Sonia Lounis Christelle Lenoir Anne-Laure Mathieu Marion Moreews Magali Perret Capucine Picard Sylvain Latour 《The Journal of allergy and clinical immunology》2021,147(2):740-743.e9
77.
Salle Sophie Sevestre Christelle Richeval Camille Hakim Florian Allorge Delphine Gaulier Jean-michel 《International journal of legal medicine》2021,135(4):1467-1470
International Journal of Legal Medicine - The detection of synthetic cannabinoid (SC) intoxication cases is challenging, even more when the involved SC identification is requested in a forensic... 相似文献
78.
Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Perry Maxwell Florinda Melendez‐Rodríguez Kyle B. Matchett Julian Aragones Nathalie Ben‐Califa Heidelinde Jaekel Ludger Hengst Herbert Lindner Andre Bernardini Ulf Brockmeier Joachim Fandrey Fritz Grunert Howard S. Oster Moshe Mittelman Mohamed El‐Tanani Markus Thiersch Edith M. Schneider Gasser Max Gassmann David Dangoor Robert J. Cuthbert Alexandra Irvine Anne Jordan Terence Lappin John Thompson Drorit Neumann 《British journal of haematology》2015,168(3):429-442
Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment. 相似文献
79.
80.
Univ.-Doz. Robert N. A. Gasser M.D. D. Phil Werner Klein 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1994,8(6):813-822
Summary In early myocardial ischemia we find a number of salient electrical and ionic alterations. This article reviews action potential shortening, K accumulation, and contractile failure. Enhanced K efflux during early myocardial ischemia has been attributed to a number of mechanisms, including: the inhibition of active K uptake, osmotic changes, efflux of K ions linked to anion extrusion, cation exchange, altered cellular energy levels, in particular, the opening of ATP-dependent K channels, the involvement of other ion channels, a H/K-ion exchanger, and a catecholamine-dependent pathway. The different mechanisms are discussed. Action potential shortening was described as a salient characteristic of myocardial ischemia in 1954 by Trautwein and Dudel, and was attributed to enhanced outward current. Recently it has been shown by several authors that ATP-dependent potassium channels play a key role in this context. Contractile failure in early myocardial ischemia has been explained by shortening of the action potential duration, reduced cytoplasmic free calcium levels, intracellular acidification, and a rise in inorganic phosphate and Mg. In summary, it is concluded that ATP-dependent K channels may be involved in each of these three phenomena. 相似文献